Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiepileptic Drugs: Calcium Channel Blockers

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.

European heart journal. Cardiovascular pharmacotherapy·2026

Same author

Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy.

The pharmacogenomics journal·2026

Same author

Amiodarone today.

Medicina clinica·2026

Same author

Cardiovascular pharmacotherapy in 2025.

European heart journal. Cardiovascular pharmacotherapy·2026

Same author

SGLT2 inhibitors: Do they have antiarrhythmic properties?

Pharmacology & therapeutics·2026

Same author

Improved Survival With Automated External Defibrillator-Only Training in a Public-Access Defibrillation Program: A 23-Year Database Analysis of Progetto Vita.

Journal of the American Heart Association·2025

Search research articles

Related Experiment Video

Updated: May 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Safety of flecainide.

Juan Tamargo¹, Alessandro Capucci, Philippe Mabo

¹Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain. jtamargo@med.ucm.es

|March 23, 2012

Summary

Flecainide is a safe and effective antiarrhythmic for atrial fibrillation (AF) when carefully selected patients without structural heart disease are treated. It offers a good safety profile with manageable risks for rhythm control.

Area of Science:

Cardiology
Pharmacology

Background:

Flecainide, a class Ic antiarrhythmic, is crucial for atrial fibrillation (AF) rhythm control.
Past concerns regarding flecainide safety in specific patient groups (post-myocardial infarction) impacted its broader use.
Current European guidelines support flecainide in selected AF patients without structural heart disease.

Purpose of the Study:

To review flecainide safety data in the literature.
To assess the current clinical utility of flecainide for managing atrial fibrillation.

Main Methods:

Literature review of safety data for flecainide.
Analysis of current European guidelines for flecainide use in AF.
Evaluation of clinical trial data for flecainide tolerability.

More Related Videos

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Related Experiment Videos

Last Updated: May 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Main Results:

Flecainide is recommended for recent-onset AF cardioversion, acute oral therapy, and rhythm maintenance in carefully selected AF patients without structural heart disease.
Potential cardiac adverse effects include proarrhythmia and conduction abnormalities; non-cardiac effects like dizziness are usually mild and transient.
Recent trials show good tolerability in appropriately selected patients, with manageable risks in renal dysfunction and drug interactions.

Conclusions:

Flecainide is a suitable pharmacological option for AF management, demonstrating a good safety record and low incidence of adverse effects.
Careful patient selection and monitoring are essential to maximize benefits and minimize risks associated with flecainide therapy.
The drug presents a low risk of ventricular proarrhythmia and rare end-organ toxicity in appropriately managed patients.